Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ryan Engel

Medical Oncology Zion, IL Doctor of Osteopathy

NPI 1740336718 CMS profile 214750

Cancer Treatment Centers Of America, 2520 Elisha Avenue, Zion, IL 60099

Open in the dashboard

General payments

$18,828

65 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$96 paid to institutions, not to them · program year 2019

Through program year 2025, Ryan Engel of Zion, IL is reported in the CMS Open Payments database as having received $18,828 across 65 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $96 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,827 15
2024 General $8,022 39
2023 General $958 10
2022 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Engel
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Ryan Engel were reported at $9,827. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Ryan Engel Medical Oncology median Middle half National median
2019 $0 $968 $140–$6,658 $163
2020 $0 $747 $102–$5,891 $114
2021 $0 $430 $50–$4,098 $132
2022 $20 $812 $127–$4,907 $149
2023 $958 $957 $144–$5,248 $160
2024 $8,022 $1,042 $149–$5,650 $164
2025 $9,827 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $6,880 9 payments
  2. Daiichi Sankyo Inc. $4,079 13 payments
  3. Avyxa Pharma, LLC $3,743 7 payments
  4. Geron Corporation $2,746 5 payments
  5. BeiGene USA, Inc. $675 1 payment
  6. Merck Sharp & Dohme Corporation $243 12 payments
  7. Pfizer Inc. $138 4 payments
  8. Tempus AI, Inc $64 3 payments
  9. Celgene Corporation $54 2 payments
  10. Genentech USA, Inc. $44 2 payments
  11. Other $162 7 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $13,818 15 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
  3. Food and Beverage $1,444 45 payments
  4. Travel and Lodging $1,366 3 payments
  5. Honoraria $200 1 payment
Products named General payments · program years 2022–2025
  1. Truqap $3,205 2 payments
  2. IMETELSTAT $2,746 5 payments
  3. IMFINZI $2,625 5 payments
  4. ENHERTU $1,526 7 payments
  5. BRUKINSA $675 1 payment
  6. Vanflyta $650 1 payment
  7. CALQUENCE $525 1 payment
  8. LYNPARZA $525 1 payment
  9. KEYTRUDA $217 11 payments
  10. INLYTA $138 4 payments
  11. Other $593 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,631

Median for Medical Oncology: 414

Drug cost

$558,412

Median for Medical Oncology: $849,427

Branded share of claims

26.2%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 23 $317,559
Abiraterone Acetate Generic 48 $89,842
Xarelto Rivaroxaban Brand 86 $73,499
Eliquis Apixaban Brand 50 $47,836
Enoxaparin Sodium Generic 13 $6,241
Valacyclovir Valacyclovir Hcl Brand 48 $4,012
Dexamethasone Generic 95 $2,479
Morphine Sulfate Er Morphine Sulfate Brand 76 $2,132
Tamoxifen Citrate Generic 68 $1,746
Letrozole Generic 94 $1,659

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$68,854

Medicare's payments for the services billed

Medicare patients

326

Average age 75

Services billed

1,615

176 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 40%
Diabetes 37%
Ischemic heart disease 37%
Chronic kidney disease 36%
Heart failure 29%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $2,625
$2,625 — —
ENHERTU
  • Daiichi Sankyo Inc. $1,526
$1,526 — —
BRUKINSA
  • BeiGene USA, Inc. $675
$675 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $525
  • Merck Sharp & Dohme Corporation $10
$535 — —
Truqap
  • AstraZeneca Pharmaceuticals LP $525
$525 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record